Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

This study has been terminated.
(The premature end of this trial was a business decision and not due to safety or efficacy concerns of the compounds.)
Information provided by:
Tibotec Pharmaceuticals, Ireland Identifier:
First received: May 21, 2009
Last updated: April 26, 2010
Last verified: April 2010
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: October 2009
  Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)